Biotinylated Human Siglec-10 Protein
Catalog No: SIGLEC10-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1), Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human Siglec-10 Protein is expressed in HEK293 cells with an hFc (IgG1) tag and Avi tag at the C-terminus. It contains amino acid residues Met17-Thr546 (UniProt accession: Q96LC7-1).
Product Details
- Molecular Aliases
- SLG2; SIGLEC10; MGC126774; PRO940
- Protein Length
- Met17-Thr546
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 85.8 kDa. Due to glycosylation, the protein migrates to 95-110 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS, 500mM L-arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human Siglec-10 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Anti-Siglec-10 Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human Siglec-10, hFc Tag with the EC50 of 0.33μg/ml determined by ELISA.
Background
Siglec-10 is a ligand for CD52, the target of the therapeutic monoclonal antibody Alemtuzumab. It is also reported to bind to Vascular adhesion protein 1 (VAP-1) and to the co-stimulatory molecule CD24 also known as HSA (Heat-stable antigen). Siglecs (sialic acid binding Ig-like lectins) are I-type lectins that belong to the immunoglobulin superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by a varying number of Ig-like C2-type domains. Siglecs 5-11 constitute the CD33/Siglec-3 related group, and are differentially expressed in the hematopoietic system.
References
- Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019 Jul 31. doi: 10.1038/s41586-019-1456-0.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.